| Zhang, Hong |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT05702489: A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza |
|
|
| Completed | 2/3 | 900 | RoW | ZX-7101A | Nanjing Zenshine Pharmaceuticals | Influenza, Human | 05/23 | 10/23 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT06670352: Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN |
|
|
| Recruiting | 2 | 80 | RoW | Placebo, HSK39297 50mgBID, HSK39297 100mgBID, HSK39297 200mgQD | Haisco Pharmaceutical Group Co., Ltd. | IgA Nephropathy (IgAN) | 11/25 | 03/26 | | |
NCT06687174: Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 72 | RoW | MY008211A tablets, MY008211A tablets matched placebo | Wuhan Createrna Science and Technology Co., Ltd | IgA Nephropathy (IgAN) | 06/26 | 01/28 | | |
NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases |
|
|
| Not yet recruiting | 1/2 | 99 | RoW | SCTC21C | Sinocelltech Ltd. | IgA Nephropathy | 09/27 | 03/29 | | |
NCT06101316: A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China |
|
|
| Recruiting | 1 | 12 | RoW | CB06-036 | Shanghai Zhimeng Biopharma, Inc. | Healthy Volunteers | 10/23 | 12/23 | | |
NCT06216041: To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects |
|
|
| Recruiting | 1 | 138 | RoW | IMM-H014, Placebo, IMM-H014 ( FE), Placebo ( FE) | Changchun Intellicrown Pharmaceutical Co. LTD | Nonalcoholic Steatohepatitis (NASH) | 07/24 | 12/24 | | |
NCT06160895: A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects |
|
|
| Completed | 1 | 40 | RoW | TQ-A3334 tablets, TQ-A3334 placebo tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B | 06/24 | 08/24 | | |
NCT06427681: An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 40 | NA | BH006 for injection, Fosaprepitant for injection+Palonosetron hydrochloride injection, EMEND®+PALONOSETRON | Zhuhai Beihai Biotech Co., Ltd | Bioavailability | 09/24 | 12/24 | | |
| Not yet recruiting | 1 | 18 | NA | AP303 150μg, AP303 300μg, Placebo 150μg, Placebo 300μg | Alebund Pharmaceuticals | Diabetic Kidney Disease | 01/25 | 01/25 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Lu, Ying |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 52 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product | Li Zhiming, Antengene Corporation | DLBCL Germinal Center B-Cell Type | 07/25 | 12/25 | | |
|
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH |
|
|
| Recruiting | 2 | 40 | RoW | ADI-PEG20, Pegargiminase, Placebo | Polaris Group | Nonalcoholic Steatohepatitis (NASH) | 12/27 | 01/28 | | |
NCT05528887: Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies |
|
|
| Recruiting | 1 | 10 | RoW | Autologous CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan | The Affiliated People's Hospital of Ningbo University, UTC Therapeutics Inc. | Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma, Leukemia | 06/24 | 06/26 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Chen, Yundai |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
NCT03574636: OCT vs IVUS vs QCA to Guide Moderate-to-severe Calcified Lesion Stent Implantation |
|
|
| Recruiting | N/A | 375 | RoW | OCT guidance, IVUS guidance, QCA | Shanghai MicroPort Medical (Group) Co., Ltd. | Optical Coherence Tomography, Intravascular Ultrasound, Angiography | 09/21 | 09/25 | | |
SUPERIOR, NCT04617899: The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria |
|
|
| Recruiting | N/A | 120 | RoW | Intravascular imaging | CardioNavi MedTech (Wuhan) Co., Ltd., Beijing Jingruitianhe Medical Science and Technology Development Co,Ltd | Coronary Artery Disease | 11/21 | 12/21 | | |
NCT04733443: The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis |
|
|
| Active, not recruiting | N/A | 310 | RoW | Biolimus, SeQuent® Please Neo | JW Medical Systems Ltd | Coronary Artery Disease | 01/23 | 02/25 | | |
| Active, not recruiting | N/A | 52 | RoW | Medtronic CoreValve™ Evolut™ PRO System | Medtronic Cardiovascular | Severe, Symptomatic Aortic Stenosis | 03/23 | 05/28 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
NCT04722796: HANGZHOU Solution in Bicuspid AS Undergoing TAVR |
|
|
| Recruiting | N/A | 508 | RoW | TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution), Hangzhou solution, TAVR with Venus A plus using annular sizing and THV implantation technique, Traditional sizing strategy (Annulus based sizing strategy) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Venus MedTech (HangZhou) Inc., First Affiliated Hospital Bengbu Medical College, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Xiamen University Affiliated Cardiovascular Hospital, Guangdong People's Hospital, Zhengzhou Cardiovascular Hospital, The First Affiliated Hospital of Zhengzhou University, Hennan Provincial Chest Hospital, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Central South University, Northern Jiangsu Province People's Hospital, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Qingdao University, Shanxi cardiovascular hospital, Tianjin Chest Hospital, Ning Bo First Hospital | Aortic Stenosis, Aortic Stenosis With Bicuspid Valve | 04/24 | 04/28 | | |
| Wang, Yan |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
NCT04228926: Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects |
|
|
| Recruiting | 2 | 105 | RoW | ZKY001 eye drops 0.3g:0.006mg, shengfatai-eye drops, the Germinal Peptide eye drops, ZKY001 eye drops 0.3g:0.012mg, ZKY001 simulated eye drops, the placebo | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Corneal Defect | 12/21 | 12/21 | | |
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 2 | 86 | RoW | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT05420324: A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma |
|
|
| Completed | 2 | 20 | RoW | YH003, Pembrolizumab, albumin paclitaxel | Eucure (Beijing) Biopharma Co., Ltd | Mucosal Melanoma | 03/24 | 03/24 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 59 | US, RoW | IMP4297(senaparib), temozolomide | Impact Therapeutics, Inc. | Advanced Solid Tumours, Small Cell Lung Cancer | 04/24 | 04/24 | | |
NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 168 | RoW | SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
NCT05126927: A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors |
|
|
| Completed | 1 | 11 | RoW | 68Ga-NODAGA-SNA006 | SmartNuclide Biopharma, The First Affiliated Hospital of Soochow University | Solid Tumor | 01/22 | 08/22 | | |
NCT05490264: [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | [68Ga]Ga-NOTA-SNA002 | SmartNuclide Biopharma, The First Affiliated Hospital of Soochow University | Solid Tumor, Positron-Emission Tomography(PET) | 06/24 | 07/24 | | |
NCT06429241: Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula |
|
|
| Recruiting | 1 | 8 | RoW | Mesenchymal Stem Cells (MSCs) | Jiangsu Topcel-KH Pharmaceutical Co., Ltd., The First Affiliated Hospital of Soochow University | Anal Fistula, Complex Perianal Fistulas, Crohn's Disease | 11/24 | 12/25 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
NCT04722796: HANGZHOU Solution in Bicuspid AS Undergoing TAVR |
|
|
| Recruiting | N/A | 508 | RoW | TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution), Hangzhou solution, TAVR with Venus A plus using annular sizing and THV implantation technique, Traditional sizing strategy (Annulus based sizing strategy) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Venus MedTech (HangZhou) Inc., First Affiliated Hospital Bengbu Medical College, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Xiamen University Affiliated Cardiovascular Hospital, Guangdong People's Hospital, Zhengzhou Cardiovascular Hospital, The First Affiliated Hospital of Zhengzhou University, Hennan Provincial Chest Hospital, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Central South University, Northern Jiangsu Province People's Hospital, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Qingdao University, Shanxi cardiovascular hospital, Tianjin Chest Hospital, Ning Bo First Hospital | Aortic Stenosis, Aortic Stenosis With Bicuspid Valve | 04/24 | 04/28 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
| Active, not recruiting | N/A | 51 | RoW | MitraClip procedure | Abbott Medical Devices | Mitral Regurgitation | 05/24 | 05/25 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Leite, Silmara AO |
| Suspended | 3 | 675 | Europe, Canada, US, RoW | Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo | Anji Pharma | Diabetes Mellitus, Type 2 | 12/23 | 06/24 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Seibold, Frank |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
| Liu, Lin |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 03/24 | 09/25 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
|
|
| Recruiting | 1 | 98 | RoW | HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study | Hutchmed | Hematological Malignancies | 10/27 | 12/27 | | |
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 06/25 | 11/25 | | |
| Martino, Vincent Di |
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites |
|
|
| Completed | 3 | 160 | Europe | Rifaximin, Placebo | Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA | Cirrhosis, Ascites, Peritonitis | 06/22 | 03/23 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Jin, Hua |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
| Wozniak-Stolarska, Barbara |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Li, Qin |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
| Jiang, Ming |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT05707832: A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus |
|
|
| Not yet recruiting | 3 | 60 | RoW | Amphotericin B cholesteryl Sulfate Complex for Injection | CSPC Ouyi Pharmaceutical Co., Ltd. | Invasive Candidiasis, Invasive Aspergillosis | 08/25 | 12/25 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Contact, Site Public |
| Completed | 4 | 50 | RoW | ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Hemophilia A | 02/23 | 02/23 | | |
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy |
|
|
| Completed | 4 | 4 | US | Digital Engagement Application (GD App), No Intervention | Takeda | Gaucher Disease | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 200 | US | CDPATH™, PROSPECT, Blood Draw | Takeda | Crohn's Disease | 10/25 | 06/26 | | |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
| Completed | 4 | 5 | RoW | Elaprase, Idursulfase | Takeda, Takeda Biopharmaceuticals India Pvt. Ltd. | Hunter Syndrome | 04/24 | 04/24 | | |
NCT06831370: A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India |
|
|
| Recruiting | 4 | 124 | RoW | Brentuximab Vedotin, Adcetris, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine | Takeda | Hodgkin Lymphoma | 03/26 | 03/26 | | |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India |
|
|
| Active, not recruiting | 4 | 5 | RoW | Replagal | Shire | Fabry Disease | 10/26 | 11/26 | | |
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer |
|
|
| Recruiting | 4 | 78 | US | Fruquintinib, Fruzaqla™ | Takeda | Colorectal Cancer | 02/28 | 02/28 | | |
| Active, not recruiting | 4 | 288 | Europe, US | Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo | Shire, Takeda Development Center Americas, Inc. | Attention Deficit Hyperactivity Disorder | 06/27 | 06/27 | | |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) |
|
|
| Recruiting | 4 | 5 | US | ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG) | Takeda, Takeda Development Center Americas, Inc. | Mucopolysaccharidosis (MPS), Hunter Syndrome | 07/28 | 07/28 | | |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
